Search results for "Brain"

showing 10 items of 3997 documents

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease.

2018

L-DOPA is still the most effective pharmacological therapy for the treatment of motor symptoms in Parkinson's disease (PD) almost four decades after it was first used. Deep brain stimulation (DBS) is a safe and highly effective treatment option in patients with PD. Even though a clear understanding of the mechanisms of both treatment methods is yet to be obtained, the combination of both treatments is the most effective standard evidenced-based therapy to date. Recent studies have demonstrated that DBS is a therapy option even in the early course of the disease, when first complications arise despite a rigorous adjustment of the pharmacological treatment. The unique feature of this therapeu…

0301 basic medicineLevodopaParkinson's diseaseDeep brain stimulationglobus pallidus internus (GPi)medicine.medical_treatmentParkinson's diseaseCentral nervous systemStimulationDiseaseReviewlcsh:RC346-42903 medical and health sciencesTherapeutic approach0302 clinical medicinemedicinelevodopadeep brain stimulation (DBS)lcsh:Neurology. Diseases of the nervous systembusiness.industryDopaminergicmedicine.diseasenervous system diseases030104 developmental biologymedicine.anatomical_structureNeurologyNeurology (clinical)businessNeurosciencesubthalamic nucleus (STN)030217 neurology & neurosurgerymedicine.drugFrontiers in neurology
researchProduct

Pre-dopa Deep Brain Stimulation: Is Early Deep Brain Stimulation Able to Modify the Natural Course of Parkinson’s Disease?

2020

Deep brain stimulation (DBS) is an established therapy for the management of Parkinson's disease (PD). However, DBS is indicated as the disease progresses and motor complications derived from pharmacological therapy arise. Here, we evaluate the potential of DBS prior to levodopa (L-Dopa) in improving quality of life (QoL), challenging the state of the art for DBS therapy. We present data on clinical manifestation, decision finding during early indication to DBS, and trajectories after DBS. We further discuss current paradigms for DBS and hypothesize on possible mechanisms. Six patients, between 50 and 67 years old, presenting at least 5 years of PD symptoms, and without L-Dopa therapy initi…

0301 basic medicineLevodopamedicine.medical_specialtyDeep brain stimulationParkinson's diseasemedicine.medical_treatmentDiseaselcsh:RC321-57103 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationQuality of lifemedicineAdverse effectlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchsubthalamic nucleusbusiness.industryGeneral Neuroscienceearly deep brain stimulationmedicine.diseasenervous system diseasesdeep brain stimulationClinical trialSubthalamic nucleusearly intervention030104 developmental biologysurgical procedures operativenervous systemParkinson’s diseasebusinesstherapeutics030217 neurology & neurosurgerymedicine.drugNeuroscienceFrontiers in Neuroscience
researchProduct

Neurodegeneration in tauopathies and synucleinopathies.

2016

International audience; While increasing life expectancy is a major achievement, the global aging of societies raises a number of medical issues, such as the development of age-related disorders, including neurodegenerative diseases. The three main disease groups constituting the majority of neurodegenerative diseases are tauopathies, alpha-synucleinopathies and diseases due to repetitions of glutamine (including Huntington's disease). In each neurodegenerative disease, the accumulation of one or more aggregated proteins has been identified as the molecular signature of the disease (as seen, for example, in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, amyotrophic lat…

0301 basic medicineLewy Body DiseaseParkinson's disease[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyParkinson's diseaseDementia with Lewy bodiesMédecine humaine et pathologieDiseaseBioinformatics03 medical and health scienceschemistry.chemical_compound0302 clinical medicineParkinsonian Disorders[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineDementiaHumansCytoskeletonSynucleinopathiesAlpha-synucleinInclusion Bodiesbusiness.industryDementia with Lewy bodiesNeurodegenerative diseasesNeurodegenerationassociationBrainNeurodegenerative DiseasesAlzheimer's diseasemedicine.disease3. Good health030104 developmental biologyNeurologychemistryTauopathies[ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyNerve Degenerationalpha-SynucleinDementiapathologyNeurology (clinical)businessNeuroscience030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFrontotemporal dementiadementiaRevue neurologique
researchProduct

Role of Microbiota-Derived Extracellular Vesicles in Gut-Brain Communication

2021

Human intestinal microbiota comprise of a dynamic population of bacterial species and other microorganisms with the capacity to interact with the rest of the organism and strongly influence the host during homeostasis and disease. Commensal and pathogenic bacteria coexist in homeostasis with the intestinal epithelium and the gastrointestinal tract’s immune system, or GALT (gut-associated lymphoid tissue), of the host. However, a disruption to this homeostasis or dysbiosis by different factors (e.g., stress, diet, use of antibiotics, age, inflammatory processes) can cause brain dysfunction given the communication between the gut and brain. Recently, extracellular vesicles (EVs) derived from …

0301 basic medicineLipopolysaccharideQH301-705.5brainReviewBiologymedicine.disease_causeCatalysisInorganic ChemistryNeuroblastoma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemmedicinemicrobiotaAnimalsHumansPhysical and Theoretical ChemistryBiology (General)ReceptorbacteriaMolecular BiologyQD1-999SpectroscopyGastrointestinal tractneuropathologyOrganic ChemistryPathogenic bacteriaGeneral Medicinemedicine.diseaseIntestinal epitheliumComputer Science ApplicationsCell biologyChemistry030104 developmental biologychemistryRNA Long Noncodingextracellular vesiclesDysbiosis030217 neurology & neurosurgeryHomeostasisInternational Journal of Molecular Sciences
researchProduct

Involvement of interleukin-1 type 1 receptors in lipopolysaccharide-induced sickness responses

2017

Sickness responses to lipopolysaccharide (LPS) were examined in mice with deletion of the interleukin (IL)-1 type 1 receptor (IL-1R1). IL-1R1 knockout (1(0) mice displayed intact anorexia and HPA-axis activation to intraperitoneally injected LPS (anorexia: 10 or 120 mu g/kg; HPA-axis: 120 mu g/kg), but showed attenuated but not extinguished fever (120 g/kg). Brain PGE2 synthesis was attenuated, but Cox-2 induction remained intact. Neither the tumor necrosis factor-alpha (TNF alpha) inhibitor etanercept nor the IL -6 receptor antibody tocilizumab abolished the LPS induced fever in IL -1R1 KO mice. Deletion of IL -1R1 specifically in brain endothelial cells attenuated the LPS induced fever, b…

0301 basic medicineLipopolysaccharidesMalemedicine.medical_specialtyLipopolysaccharideFeverCell- och molekylärbiologiImmunologyHypothalamusAnorexiaEtanerceptInterleukin-1 type 1 receptor; Lipopolysaccharide; Fever; Anorexia; ACTH; Corticosterone; Endothelial cells; THF alpha; Interleukin-6; PGE(2)03 medical and health sciencesBehavioral Neurosciencechemistry.chemical_compoundEating0302 clinical medicineAdrenocorticotropic HormoneCorticosteroneInternal medicinemedicineJournal ArticleAnimalsInterleukin 6ReceptorIllness BehaviorInflammationMice KnockoutReceptors Interleukin-1 Type IbiologyEndocrine and Autonomic Systemsbusiness.industryInterleukinBrainEndothelial CellsAnorexia030104 developmental biologyEndocrinologychemistrybiology.proteinTumor necrosis factor alphaFemalemedicine.symptomInflammation MediatorsbusinessCorticosterone030217 neurology & neurosurgeryCell and Molecular Biologymedicine.drug
researchProduct

7,8-hydroxy-2′-deoxyguanosine/2′-deoxiguanosine ratio determined in hydrolysates of brain DNA by ultrachromatrography coupled to tandem mass spectrom…

2017

7,8-hydroxy-2'-deoxyguanosine (8-OHdG) is an abundant DNA lesion formed by oxidation of the nucleoside 2'-deoxyguanosine (2-dG) and one of the most studied and accepted oxidative stress biomarkers. 8-OHdG has a strong carcinogenic potential, and prolonged oxidative stress heightens pathological conditions and especially cancer risk. Our aim was to develop, validate and apply a reliable method to assess DNA oxidation in genomic cellular DNA of sensible target organs such as brain. A procedure to isolate and digest the DNA of brain tissue properly for further detection of 8-OHdG and 2-dG by Ultra Performance Liquid Chromatography tandem Mass Spectrometry (UPLC-MS/MS) was optimized. The UPLC-M…

0301 basic medicineLiquid chromatographyTandem mass spectrometrymedicine.disease_causeAnalytical ChemistryMice03 medical and health scienceschemistry.chemical_compoundTandem Mass SpectrometrymedicineAnimalsDeoxyguanosineDNA oxidationChromatography High Pressure LiquidCarcinogenAsphyxiaTissueMass spectrometryChemistryHydrolysisBrainDeoxyguanosine8-Hydroxy-2'-deoxyguanosineDNADNA oxidationMolecular biologyMice Inbred C57BL030104 developmental biologyBiochemistry8-Hydroxy-2'-Deoxyguanosine78-hydroxy-2 '-deoxyguanosinemedicine.symptomBiomarkersDNAOxidative stress8-OHdGTalanta
researchProduct

Maternal Caloric Restriction Implemented during the Preconceptional and Pregnancy Period Alters Hypothalamic and Hippocampal Endocannabinoid Levels a…

2016

Journal Article; Exposure to inadequate nutritional conditions in critical windows of development has been associated to disturbances on metabolism and behavior in the offspring later in life. The role of the endocannabinoid system, a known regulator of energy expenditure and adaptive behaviors, in the modulation of these processes is unknown. In the present study, we investigated the impact of exposing rat dams to diet restriction (20% less calories than standard diet) during pre-gestational and gestational periods on: (a) neonatal outcomes; (b) endocannabinoid content in hypothalamus, hippocampus and olfactory bulb at birth; (c) metabolism-related parameters; and (d) behavior in adult mal…

0301 basic medicineLitter (animal)hippocampuschemistry.chemical_compoundBehavioral Neuroscience0302 clinical medicineMaternal urdernutrition:Phenomena and Processes::Metabolic Phenomena::Body Composition::Body Fat Distribution::Adiposity [Medical Subject Headings]rathypothalamus:Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproductive Physiological Processes::Reproduction::Pregnancy [Medical Subject Headings]Original Research:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Adaptation Psychological [Medical Subject Headings]Endocannabinoid systemOlfactory BulbEndocannabinoidesNeuropsychology and Physiological PsychologyAdiposidadGestationmedicine.symptomRestricción calórica:Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids Unsaturated::Arachidonic Acids [Medical Subject Headings]medicine.medical_specialtyOffspringEmbarazo:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Energy Intake::Caloric Restriction [Medical Subject Headings]Cognitive NeuroscienceHypothalamusBiologyDevelopmentlcsh:RC321-57103 medical and health sciencesAnsiedadRatasHyppocampusInternal medicinemedicineHipocampoÁcidos araquidónicos:Anatomy::Nervous System::Central Nervous System::Brain::Limbic System::Hippocampus [Medical Subject Headings]endocannabinoids:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Emotions::Anxiety [Medical Subject Headings]lcsh:Neurosciences. Biological psychiatry. NeuropsychiatrydevelopmentPregnancyPalmitoylethanolamideBehavior:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Endocannabinoids [Medical Subject Headings]behaviorMetabolismo Energético:Phenomena and Processes::Metabolic Phenomena::Metabolism::Energy Metabolism [Medical Subject Headings]maternal undernutrition:Anatomy::Nervous System::Central Nervous System::Brain::Limbic System::Hypothalamus [Medical Subject Headings]medicine.diseaseAdaptación psicológicaOlfactory bulb030104 developmental biologyEndocrinologyMetabolism:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Rats [Medical Subject Headings]chemistryRatWeight gainmetabolism030217 neurology & neurosurgeryHipotálamoEndocannabinoidsNeuroscienceFrontiers in Behavioral Neuroscience
researchProduct

Central nervous system involvement in ALK-rearranged NSCLC : promising strategies to overcome crizotinib resistance

2016

ABSTRACT: Introduction: ALK rearranged Non Small Cell Lung Cancers (NSCLCs) represent a distinct subgroup of patients with peculiar clinic-pathological features. These patients exhibit dramatic responses when treated with the ALK tyrosine kinase inhibitor Crizotinib, albeit Central Nervous System (CNS) activity is much less impressive than that observed against extracranial lesions. CNS involvement has become increasingly observed in these patients, given their prolonged survival. Several novel generation ALK inhibitors have been developing to increase CNS penetration and to provide more complete ALK inhibition. Areas covered: The CNS activity of Crizotinib and novel generation ALK inhibito…

0301 basic medicineLung NeoplasmsSettore MED/06 - Oncologia MedicaPyridinesPyridineDrug ResistanceNSCLCTyrosine-kinase inhibitorALK translocations Brain metastases central nervous system metastases leptomeningeal metastases NSCLC Animals Antineoplastic Agents Brain Neoplasms Carcinoma Non-Small-Cell Lung Drug Design Drug Resistance Neoplasm Gene Rearrangement Humans Lung Neoplasms Protein Kinase Inhibitors Pyrazoles Pyridines Receptor Protein-Tyrosine Kinases Oncology Pharmacology (medical)Cns penetrationAntineoplastic Agent0302 clinical medicinecentral nervous system metastasesCarcinoma Non-Small-Cell Lunghemic and lymphatic diseasesMedicinePharmacology (medical)Anaplastic Lymphoma Kinaseleptomeningeal metastaseNon-Small-Cell LungGene RearrangementBrain NeoplasmsReceptor Protein-Tyrosine Kinasemedicine.anatomical_structureOncology030220 oncology & carcinogenesisNon small cellHumanmedicine.drugBrain metastasemedicine.drug_classCentral nervous systemProtein Kinase InhibitorCNS InvolvementAntineoplastic AgentsALK translocationBrain Neoplasm03 medical and health sciencesCrizotinibAnimalsHumansCns activityCrizotinib resistanceProtein Kinase Inhibitorsleptomeningeal metastasescentral nervous system metastaseCrizotinibAnimalbusiness.industryCarcinomaReceptor Protein-Tyrosine KinasesBrain metastasesLung Neoplasm030104 developmental biologyALK translocationsDrug Resistance NeoplasmDrug DesignPyrazoleImmunologyCancer researchNeoplasmPyrazolesHuman medicinebusinessExpert review of anticancer therapy
researchProduct

Biallelic variants in LARS2 and KARS cause deafness and (ovario)leukodystrophy

2019

Supplemental Digital Content is available in the text.

0301 basic medicineLysine-tRNA LigaseMalePathologyMagnetic Resonance SpectroscopyMedizinmembrane proteins030204 cardiovascular system & hematologyMitochondrionDeafnessmedicine.disease_causeCompound heterozygosityCorrectionsLeukoencephalopathyMyelin0302 clinical medicineCytosolLeukoencephalopathies030212 general & internal medicineOvarian DiseasesTransfer RNA AminoacylationChildZebrafishMUTATIONExome sequencing10012MutationBrainMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]General MedicineMiddle AgedDisorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]Magnetic Resonance ImagingMitochondriaProtein Transportendoplasmic reticulummedicine.anatomical_structureChild PreschoolTransfer RNAComputingMethodologies_DOCUMENTANDTEXTPROCESSING/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Biological AssayFemaleWRBRare cancers Radboud Institute for Health Sciences [Radboudumc 9]Adultcardiomyopathiesmedicine.medical_specialtyMitochondrial diseaseAminoacylationMuscle disorderBiologyArticleMEDIATES INSERTIONAmino Acyl-tRNA Synthetases03 medical and health sciencesSDG 3 - Good Health and Well-beingmedicineAnimalsPoint MutationHumansAmino Acid SequenceAlleleAllelesCOMPLEXGenetic heterogeneitybusiness.industryArsenite Transporting ATPasesLeukodystrophyGenetic Variation10090Original ArticlesZebrafish Proteinsbiology.organism_classificationDILATED CARDIOMYOPATHYmedicine.diseasezebrafishGENEMolecular biologyDisease Models Animal030104 developmental biologyMembrane protein[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics10084Neurology (clinical)Transfer RNA AminoacylationMEMBRANEbusinessSequence Alignment030217 neurology & neurosurgeryexomeNeurology
researchProduct

Molecular mechanisms underlying the neuroprotective role of atrial natriuretic peptide in experimental acute ischemic stroke

2018

Abstract Along with its role in regulating blood pressure and fluid homeostasis, the natriuretic peptide system could be also part of an endogenous protective mechanism against brain damage. We aimed to assess the possibility that exogenous atrial natriuretic peptide (ANP) could protect against acute ischemic stroke, as well as the molecular mechanisms involved. Three groups of rats subjected to transient middle cerebral artery occlusion (tMCAO, intraluminal filament technique, 60 min) received intracerebroventricular vehicle, low-dose ANP (0.5 nmol) or high-dose ANP (2.5 nmol), at 30 min reperfusion. Neurofunctional condition, and brain infarct and edema volumes were measured at 24 h after…

0301 basic medicineMAPK/ERK pathwayMalePotassium ChannelsSignaling pathwaysmedicine.drug_classMAP Kinase Signaling SystemAcute ischemic strokeDown-RegulationApoptosisBrain damagePharmacologyBiochemistryNeuroprotectionBrain Ischemia03 medical and health sciencesPhosphatidylinositol 3-Kinases0302 clinical medicineEndocrinologyAtrial natriuretic peptideNatriuretic peptideMedicineAnimalsDNA CleavageRats WistarReceptorAtrial natriuretic peptideMolecular BiologyProtein kinase BPI3K/AKT/mTOR pathwayInjections Intraventricularbusiness.industryCaspase 3Natriuretic peptide receptorsBrainInfarction Middle Cerebral ArteryStroke030104 developmental biologyNeuroprotective AgentsReperfusion InjuryK+ channelsmedicine.symptombusinessProto-Oncogene Proteins c-aktReceptors Atrial Natriuretic Factor030217 neurology & neurosurgeryAtrial Natriuretic Factorhormones hormone substitutes and hormone antagonists
researchProduct